Biohaven R&D Day at Yale School of Management: Insights and Updates from Bloomberg Expert

Biohaven Pharmaceuticals held an R&D Day at Yale School of Management on May 28, 2025. The event included a presentation that has been updated at 1:05 PM ET and can be viewed online. The presentation featured images of the event.

Biohaven Pharmaceuticals (BHVN) held its 2025 R&D Day at Yale School of Management on May 28, 2025, providing updates on its oncology development programs. The presentation, which was updated at 1:05 PM ET and available online, highlighted the progress of two innovative antibody-drug conjugates (ADCs) incorporating the proprietary TopoIx payload.

The company reported encouraging preliminary clinical activity and a favorable safety profile for BHV-1510, a Trop2 ADC. As a monotherapy and in combination with Regeneron's anti-PD-1 antibody cemiplimab, BHV-1510 demonstrated tumor reduction in 6 out of 6 patients, including confirmed partial responses. The combination therapy showed anti-tumor activity in patients with brain metastasis, and the majority of patients had failed prior anti–PD-1/PD-L1 therapies. The Phase 1 study of BHV-1510 showed a favorable pharmacokinetic (PK) profile and manageable toxicity, with no cases of payload-associated interstitial lung disease.

Biohaven also announced the first patient has been dosed in the Phase 1 study of BHV-1530, an FGFR3-directed ADC. BHV-1530 has potential in indications of cancers driven by FGFR3 alterations and/or upregulated FGFR3 protein expression, including urothelial cancers and other solid tumors. This is the first FGFR3 ADC advanced in clinical testing.

The company is also advancing a portfolio of innovative technologies through strategic collaborations with Merus and GeneQuantum. These collaborations aim to modernize next-generation ADCs, leveraging Biohaven's differentiated ADC platform and TopoIx payload.

Biohaven's President of Oncology, Brian Lestini, M.D., Ph.D., commented on the early clinical experience with BHV-1510, stating, "The early clinical data with BHV-1510 dosed in patients who failed standard of care treatment are highly encouraging, particularly the observed potential synergy with anti-PD-1 therapy."

The forward-looking statements included in the news release should be considered with caution, as they involve substantial risks and uncertainties, including the expected timing and outcomes of clinical trials, regulatory filings, and the commercialization of Biohaven's product candidates.

References:
[1] https://ir.biohaven.com/news-releases/news-release-details/biohaven-presents-oncology-program-updates-and-preliminary